Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-24Clinical Trial Update: Cognitive Bias Modification for OCD [NA]
The clinical trial NCT03799419 investigating cognitive bias modification for Obsessive-Compulsive Disorder has completed.
-
CLINICAL_TRIALS research · 2024-07-19Clinical Trial Update: Neural Mechanisms of Response Inhibition Training for OCRD [NA]
This clinical trial update reports on a study examining neural mechanisms of response inhibition training for obsessive-compulsive and relat…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD): Improving Targeting Precision [NA]
A clinical trial update on using deep brain stimulation to treat obsessive-compulsive disorder, focusing on improving targeting precision; e…
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD).
A clinical trial update presents long-term follow-up results for deep brain stimulation in obsessive-compulsive disorder, detailing extended…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Psychiatric Neurosurgery (PNS) for Obsessive Compulsive Disorder (OCD): A Qualitative Analysis of Patient and Family Member Experiences
This clinical trial update notes that a study evaluating psychiatric neurosurgery for obsessive-compulsive disorder is currently recruiting …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: BIP in Jämtland Härjedalen: Increased Access to CBT Within Regular Health Care in Northern Sweden [NA]
A Karolinska Institutet study in Northern Sweden reports increased access to cognitive behavioral therapy within regular health care in Jämt…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Towards Remission and Full Recovery From Obsessive-compulsive Disorder [NA]
A clinical trial aiming for remission and full recovery from obsessive-compulsive disorder is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: Treatment Effects of Family Based Cognitive Therapy in Children and Adolescents With Obsessive Compulsive Disorder [NA]
This clinical trial update describes treatment effects of family-based cognitive therapy for obsessive-compulsive disorder in children and a…
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: Effectiveness of a Self-guided Mobile Application in Improving Obsessive Compulsive Disorder Symptoms [NA]
This clinical trial update from the National University of Singapore evaluates the effectiveness of a self-guided mobile application to impr…
-
CLINICAL_TRIALS trial_result · 2024-06-26Clinical Trial Update: Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment
This completed clinical trial evaluated outcomes of exposure and response prevention delivered via video teletherapy for obsessive-compulsiv…
-
CLINICAL_TRIALS research · 2024-06-20Clinical Trial Update: Metacognitive Therapy for Obsessive-Compulsive Disorder [NA]
This clinical trial is evaluating metacognitive therapy for obsessive-compulsive disorder. The study is currently recruiting.
-
FDA label_change · 2024-06-12FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for PAROXETINE HYDROCHLORIDE submitted by Zydus Lifesciences Limited, resulting in changes to the pr…
-
CLINICAL_TRIALS withdrawal · 2024-05-21Clinical Trial Update: Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating cannabinoid target engagement in adults with Obsessive-Compulsive Disorder has been withdrawn.
-
CLINICAL_TRIALS research · 2024-05-13Clinical Trial Update: Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery
This ongoing clinical study uses microelectrode recording during deep brain stimulation surgery to measure sensory gating and explore neural…
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: Pharmacogenetics of Antidepressant-Induced Disinhibition
A recruitment study investigating how pharmacogenetics influence antidepressant-induced disinhibition. It targets obsessive-compulsive disor…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: Neural Correlates of Compulsivity
Columbia University-sponsored study on the neural correlates of compulsivity in obsessive-compulsive disorder has completed.
-
FDA approval · 2024-05-02FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for the generic fluoxetine from Aurobindo Pharma Limited (ANDA213265).
-
CLINICAL_TRIALS research · 2024-05-02Clinical Trial Update: An Automated Navigation System for Deep Brain Electrode Implantation
A clinical trial is evaluating an automated navigation system for deep brain electrode implantation in Parkinson's disease, epilepsy, and ob…
-
FDA approval · 2024-04-05FDA Approved: FLUOXETINE — Original Application (Strides Pharma Science Limited)
FDA approved an Original Application for a generic Fluoxetine from Strides Pharma Science Limited, enabling a generic version of fluoxetine …
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Predicting Treatment Response in Patients With OCD [Phase 4]
A Phase 4 clinical trial investigated predictors of treatment response in obsessive-compulsive disorder, with completed status.
-
CLINICAL_TRIALS trial_result · 2024-02-23Clinical Trial Update: Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder [Phase 2]
Phase 2 safety study of RG1068 in obsessive-compulsive disorder has completed.
-
FDA approval · 2024-02-02FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for sertraline hydrochloride from Rising Pharma Holdings, Inc., resulting in approval of a gener…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Does TMS Affect Neuroplasticity? The Role of Brain-derived Neurotrophic Factor and Neuronal Cell Adhesion Molecules - an Intensive Clinical Protocol Among Patients With Obsessive-compulsive Disorders [Phase 4]
Phase 4 clinical trial evaluating the impact of transcranial magnetic stimulation on neuroplasticity in obsessive-compulsive disorder.
-
FDA approval · 2024-01-22FDA Approved: FLUVOXAMINE MALEATE — Original Application (Bionpharma Inc.)
The FDA approved the original ANDA for fluvoxamine maleate from Bionpharma Inc. as a generic version of fluvoxamine, indicated for obsessive…
-
FDA approval · 2024-01-19FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Paroxetine by ANI Pharmaceuticals, Inc., indicating approval of a generic product under ANDA 215…